Centre intégré universitaire de santé et de services sociaux de l’Ouest-de-l’Île-de-Montréal
Accueil Plan du site Courrier Portail Québec Passer directement au contenu

Clinical Studies
Molecular biomarkers of antidepressant response

Principal investigator : Gustavo Turecki


Description of the study :

Major depression is quite prevalent in the general population and is clearly associated to important consequences in our society. Treatment with antidepressants remains the most common treatment for depressive episodes. In addition, antidepressants are among the most commonly prescribed medications in North America.

This research project will allow us to better understand how individuals suffering from major depression differentiate themselves in terms of their response to antidepressant treatment. As such, the focus will be on two commonly prescribed antidepressants, both of which are already available on the market, in order to compare the molecular markers which differentiate those who respond to antidepressant treatment and those who do not.

Financial compensations : yes
Eligibility criteria :

  • Between 18 and 65 years of age;
  • Exhibit certain symptoms of depression: Sadness, hopelessness, loss of interest, feelings of guilt, failure, dissatisfaction, sleep disturbances, changes in appetite, concentration, indecision, fatigue and suicidal ideation.
  • Available for 5 interviews and 4 blood draws (genetic screening);
  • No illegal drug consumption in the last three months;
  • Willingness to receive a known antidepressant treatment, currently on the market, at recommended doses (medication will be provided free of charge for 8 weeks).
Information :

To participate in the study, please contact :

Iliana Lilova
Research coordinator
Phone : 514 761-6131, poste 4468
iliana_dot_lilova_At_douglas_dot_mcgill_dot_ca

<< Back
path
send
share
share